Andrew Morey, portfolio manager at ASTON LMCG Small Cap Growth Fund, attributes the rally in U.S. biotech shares to "fundamental merits" like clinical advances.» Read More
Jamie Dinan, York Capital founder and CEO, discusses some of his firm's top stock picks. Among the names, he likes the Kraft Foods Group-Heinz deal, as well as McDonald's, which he says is now in the "show me" category.
Jamie Dinan, York Capital founder and CEO, discusses the advancements in biotechnology, and high stock valuations. He says shorting the biotech ETF can be dangerous.
Teva Pharmaceutical is buying Auspex Pharmaceuticals, reports CNBC's Joe Kernen.
After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
After speaking with the Genfit CEO, CNBC's Meg Tirrell discusses the company's future and the potential opportunity.
A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a year.
For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Eric Schmidt, Cowen & Company analyst, provides perspective on the biotech space after the Nasdaq biotech index posted its worst daily drop since December.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
"Fast Money" traders discussed how to play Wednesday's selloff in biotech, transportation and technology names.
Janet Yellen may be right … about eight months late though.
CNBC screened the large cap S&P 500 index to see where the hottest parts of the dividend stock market have been.
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.
Jean-Jacques Bienaime, BioMarin Pharmaceuticals CEO, discusses his company's bull run and new drugs to treat rare diseases, including Duchenne muscular dystrophy.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.
Why the biotech space still has room to run, with John Stoltzfus, Oppeneimer, and the "Closing Bell" panel.
Get the best of CNBC in your inbox